Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Consensus Recommendation of “Hold” by Analysts

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have been given a consensus rating of “Hold” by the seven research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $4.50.

A number of research firms have recently commented on INO. Wall Street Zen cut Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Oppenheimer restated an “outperform” rating on shares of Inovio Pharmaceuticals in a report on Friday, March 13th. Finally, Weiss Ratings cut shares of Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th.

Institutional Investors Weigh In On Inovio Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Boxer Capital Management LLC purchased a new stake in Inovio Pharmaceuticals in the third quarter worth about $5,382,000. GSA Capital Partners LLP grew its holdings in Inovio Pharmaceuticals by 171.4% in the third quarter. GSA Capital Partners LLP now owns 443,104 shares of the biopharmaceutical company’s stock worth $1,037,000 after purchasing an additional 279,844 shares during the period. MCF Advisors LLC bought a new position in Inovio Pharmaceuticals during the 3rd quarter valued at approximately $26,000. SG Americas Securities LLC bought a new position in Inovio Pharmaceuticals during the 3rd quarter valued at approximately $27,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Inovio Pharmaceuticals by 39.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 5,894 shares in the last quarter. Hedge funds and other institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Price Performance

INO stock opened at $1.31 on Friday. The company has a market cap of $107.77 million, a P/E ratio of -0.90 and a beta of 1.43. The firm has a 50-day moving average of $1.30 and a 200 day moving average of $1.63. Inovio Pharmaceuticals has a 1 year low of $1.03 and a 1 year high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02. On average, equities research analysts expect that Inovio Pharmaceuticals will post -0.98 earnings per share for the current fiscal year.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.